The 2026 Rankings at a Glance
The landscape of weight loss medications has never been more advanced — or more confusing. In 2026, patients have access to more effective, better-tolerated options than at any point in history. GLP-1 receptor agonists have fundamentally changed what is possible for people living with obesity, delivering results that were once achievable only through bariatric surgery.
This guide ranks and compares the leading weight loss medications available in 2026, drawing on the latest clinical trial data, real-world evidence, and cost information. Whether you are considering starting treatment or switching medications, this resource gives you the full picture.
Tirzepatide (Compounded)
20–22% average body weight loss · Dual GIP + GLP-1 receptor agonist · Most effective available
Semaglutide Injectable (Compounded)
15–17% average body weight loss · Strong efficacy, excellent safety profile
Oral Tirzepatide
~20% average body weight loss · Dual-action, no injections required
Oral Semaglutide
~15% average body weight loss · Needle-free GLP-1 option, daily tablet
Liraglutide (Saxenda)
5–8% average body weight loss · FDA-approved, daily injection, less effective than GLP-1 alternatives
#1: Tirzepatide — The Current Gold Standard
Tirzepatide holds the top position in 2026 by a meaningful margin. It is a dual agonist, activating both the GLP-1 (glucagon-like peptide-1) receptor and the GIP (glucose-dependent insulinotropic polypeptide) receptor simultaneously. This dual mechanism produces synergistic effects on appetite suppression and metabolic function that exceed what a single GLP-1 agonist can achieve alone.
The SURMOUNT-1 clinical trial was a landmark study: over 72 weeks, participants receiving tirzepatide 15mg lost an average of 22.5% of their body weight — roughly equivalent to losing 50 pounds for a 220-pound person. Even the 5mg and 10mg doses produced impressive results at 15.0% and 19.5% weight loss, respectively. Crucially, nearly 57% of participants on the highest dose lost at least 20% of their body weight, a threshold previously associated only with bariatric surgery.
Beyond weight, tirzepatide produces significant improvements in cardiometabolic health markers including fasting blood glucose, HbA1c, triglycerides, blood pressure, and waist circumference.
💊 Luma Health offers physician-prescribed compounded Tirzepatide — the same dual GIP/GLP-1 active molecule — at $165/month, compared to brand-name Zepbound at $1,000–$1,300/month. Learn more →
Tirzepatide at a Glance
#2 & #3: Semaglutide — Injectable and Oral Options
Semaglutide remains a dominant medication in 2026, backed by the most robust long-term safety and efficacy data of any GLP-1 drug. The STEP 1 trial demonstrated 14.9% average weight loss over 68 weeks with semaglutide 2.4mg, with 86.4% of participants losing at least 5% and 50.5% losing at least 15%.
Semaglutide also carries extensive cardiovascular outcomes data from the SELECT trial, which showed a 20% reduction in major adverse cardiovascular events in people with pre-existing heart disease — making it a particularly strong choice for patients with cardiac risk factors.
Compounded semaglutide uses the same active molecule and works identically in the body. For patients who cannot afford brand-name Wegovy at $900–$1,100/month, compounded semaglutide from a licensed compounding pharmacy offers a clinically equivalent option at a fraction of the cost. Luma Health offers this at $90/month — all-inclusive with free shipping.
Oral semaglutide delivers the same GLP-1 mechanism without injections — ideal for patients with needle aversion. Luma Health offers oral semaglutide at $100/month. Oral tirzepatide — the most powerful dual-action option in pill form — is also available at $100/month.
💊 Luma Health is one of the few platforms offering both injectable and oral options for semaglutide and tirzepatide — giving patients full flexibility to choose the delivery method that works for them.
Full Comparison Table: Top Weight Loss Medications 2026
| Medication | Avg. Weight Loss | Dosing | Brand Cost/mo | Luma Cost/mo |
|---|---|---|---|---|
| Tirzepatide (injectable) | 20–22% | Weekly injection | $1,000–$1,300 | $165 |
| Semaglutide (injectable) | 15–17% | Weekly injection | $900–$1,100 | $90 |
| Oral Tirzepatide | ~20% | Daily pill | N/A (compounded) | $100 |
| Oral Semaglutide | ~15% | Daily pill | $800–$1,000 (est.) | $100 |
| Liraglutide (Saxenda) | 5–8% | Daily injection | $600–$900 | Not offered |
| Orforglipron (pipeline) | ~14% (trial data) | Daily pill, no restrictions | TBD (2026 FDA review) | TBD |
Cost Comparison: Making GLP-1 Medications Affordable
Cost remains the primary barrier for most people considering GLP-1 medications in 2026. Brand-name GLP-1 injections carry list prices that put them out of reach for the uninsured or underinsured. Wegovy carries a list price of approximately $900–$1,100 per month. Zepbound (tirzepatide for obesity) runs $1,000–$1,300 monthly.
Physician-prescribed compounded semaglutide and tirzepatide have emerged as the primary cost solution. Prepared by licensed compounding pharmacies, these formulations contain the same active molecules at a fraction of the cost. Luma Health offers the lowest all-inclusive pricing among major telehealth GLP-1 providers — with free shipping and no contracts.
| Provider | Semaglutide/mo | Tirzepatide/mo | Shipping | 12-Month Sema Total |
|---|---|---|---|---|
| Brand Name (Wegovy/Zepbound) | $900–$1,100 | $1,000–$1,300 | Varies | $10,800–$13,200 |
| Ro Body | $149–$199 | $249–$299 | Paid | $1,788–$2,388 |
| Sequence | $249–$349 | $349–$399 | Paid | $2,988–$4,188 |
| Luma Health | $90 | $165 | Free 2–3 days | $1,080 |
Bottom line on cost: Over 12 months, Luma Health's $90/mo semaglutide saves $708–$1,308 vs Ro, $1,908–$3,108 vs Sequence, and $9,720–$12,120 vs brand-name Wegovy — for the same physician-prescribed, clinically equivalent compounded medication.
New and Emerging Medications in 2026
The GLP-1 pipeline is more exciting now than it was three years ago. Several next-generation candidates are advancing through late-stage trials, each offering potential advantages in efficacy, convenience, or accessibility.
Orforglipron (Eli Lilly)
Perhaps the most anticipated near-term approval. It is a non-peptide, small-molecule GLP-1 receptor agonist that can be taken orally without any food or water restrictions — unlike oral semaglutide (Rybelsus), which requires 30 minutes of fasting. Phase 3 ATTAIN trials showed approximately 14.7% weight loss over 36 weeks. FDA review is expected in 2026.
Retatrutide (Eli Lilly)
A triple agonist (GIP/GLP-1/glucagon) that takes tirzepatide's dual mechanism one step further. Phase 2 data showed extraordinary results — up to 24% weight loss over 48 weeks, with some participants approaching 30% body weight reduction. Phase 3 TRIUMPH trials are ongoing, with potential approval in the 2027–2028 timeframe.
CagriSema (cagrilintide + semaglutide)
A combination of amylin analogue and semaglutide that showed approximately 22.7% weight loss in Phase 3 REDEFINE trials. This pairing leverages complementary mechanisms — GLP-1 receptor agonism and amylin signaling — which slows gastric emptying and enhances satiety through different pathways.
Who Qualifies and How to Choose
FDA-approved weight loss medications are indicated for adults with a BMI of 30 or higher (obesity), or a BMI of 27 or higher with at least one weight-related health condition such as type 2 diabetes, high blood pressure, sleep apnea, high cholesterol, or cardiovascular disease.
Choose Tirzepatide If
You want maximum weight loss potential and can tolerate weekly injections. It is also the preferred choice for patients with type 2 diabetes who need the best glucose control alongside weight loss. Tirzepatide consistently outperforms semaglutide in head-to-head comparison data. Luma Health offers compounded tirzepatide at $165/month.
Choose Semaglutide If
You have established cardiovascular disease and want the proven SELECT trial data behind you, or if tirzepatide is unavailable or unaffordable. Semaglutide is also well-suited for patients who have already started it and are seeing good results. Luma Health offers compounded injectable semaglutide at $90/month.
Choose an Oral Option If
Needle aversion is a significant barrier to treatment. Luma Health offers both oral semaglutide and oral tirzepatide at $100/month — delivering the same clinically studied active molecules without any injections, ever.
- Tirzepatide is the most effective weight loss medication available in 2026, averaging 20–22% body weight reduction in clinical trials.
- Compounded semaglutide and tirzepatide contain the same active molecules as brand-name Wegovy and Zepbound at a fraction of the cost.
- Luma Health offers the lowest all-inclusive pricing: semaglutide $90/mo, tirzepatide $165/mo, oral options $100/mo.
- Both injectable and oral options are available through Luma Health — the only platform offering all four GLP-1 delivery formats.
- Emerging drugs like retatrutide (triple agonist) and orforglipron (no-restriction oral GLP-1) may expand options further in 2027–2028.
- GLP-1 medications are most effective when maintained long-term — weight typically returns after stopping treatment.
Frequently Asked Questions
Tirzepatide is currently the most effective weight loss medication available, producing average weight loss of 20–22% of body weight in clinical trials (SURMOUNT-1). Its dual GIP and GLP-1 receptor agonism makes it superior to semaglutide alone for most patients. Luma Health offers physician-prescribed compounded tirzepatide at $165/month — the same active molecule as Zepbound at a fraction of the brand price.
Compounded semaglutide uses the same active molecule and works through the same GLP-1 mechanism. Clinical evidence from Wegovy trials directly applies. Real-world outcomes are comparable when sourced from licensed compounding pharmacies. Luma Health works with VialsRX, a licensed Texas compounding pharmacy, and all medications are prescribed by Wasef Health, PC.
Standard eligibility is BMI ≥30 (obesity), or BMI ≥27 with at least one weight-related condition such as type 2 diabetes, hypertension, sleep apnea, dyslipidemia, or cardiovascular disease. A Luma Health licensed provider will review your health profile and determine the appropriate treatment during your free assessment.
Brand-name options like Wegovy and Zepbound cost $900–$1,300/month without insurance. Compounded semaglutide through Luma Health is $90/month. Compounded tirzepatide is $165/month. Oral options (semaglutide or tirzepatide) are $100/month. All Luma plans include free shipping and 24/7 care team access with no contracts.
Orforglipron (Eli Lilly) — a non-peptide oral GLP-1 agonist with no food restrictions — is under FDA review in 2026. Retatrutide (triple GIP/GLP-1/glucagon agonist) showed up to 24% weight loss in Phase 2 trials and is advancing through Phase 3. CagriSema (cagrilintide + semaglutide combination) showed 22.7% weight loss in Phase 3 REDEFINE trials.
The most common side effects are gastrointestinal: nausea, vomiting, diarrhea, and constipation. These are typically worst during dose escalation and improve over time as your body adjusts. Serious but rare risks include pancreatitis and gallbladder disease. Starting at a low dose and titrating gradually — as all Luma providers do — significantly reduces early side effect severity.
GLP-1 medications are most effective when taken long-term. Studies like STEP 4 showed that patients who stopped semaglutide regained most of the lost weight within a year. Most obesity medicine specialists now consider GLP-1 therapy a chronic treatment, similar to blood pressure or cholesterol medication. Luma Health offers month-to-month plans with no contracts so you can continue on your own timeline.